sofosbuvir (SOF)

FDA Approved for use in HIV/HCV co-infection
  • 1
  • 2
  • 3
  • 4

Standard Dose

Sovaldi is almost never prescribed separately, but instead prescribed as part of co-formulated tablets that contain it with an additional DAA: Epclusa, Harvoni, and Vosevi. Sovaldi is taken as one 400 mg tablet once daily with or without food. Sovaldi should never be taken by itself and must be taken in combination with another DAA. Sovaldi is FDA approved for treatment of HCV genotypes 2 and 3 in pediatric patients down to 3 years old and there are recommendations for dosing in children weighing less than 37.4 pounds (17 kg).

Take missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose.

Black Box Warning

Before starting treatment with any direct-acting antiviral (DAA), including Sovaldi, patients should take a blood test to check for hepatitis B (HBV) infection. HBV infection could get worse or reactivate during or after DAA treatment, potentially leading to serious liver problems, including liver failure or death. Patients with current or past HBV infection should be monitored during HCV DAA treatment, and some may need to take HBV treatment. See HBV Reactivation for more information and consult your medical provider.

Available co-formulated tablets and their components

Harvoni            Ledipasvir + sofosbuvir

Epclusa           Velpatasvir + sofosbuvir

Vosevi             Velpatasvir + sofosbuvir + voxilaprevir

Notes: Sovaldi may be used as an alternative regimen with Olysio (genotype 1) or Daklinza (genotypes 1, 2, 3). See for more information on current recommendations. For pediatric patients, Sovaldi is still recommended in combination with weight-based ribavirin for treatment of genotypes 2 and 3.


Gilead Sciences


brand: $33,600 / month

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information